INGELHEIM, GERMANY — A report titled Innovation at a Crossroads, commissioned by Boehringer and released by EY, analyzes the impact of policy choices on healthcare, economy, and strategic autonomy in the EU and compares them with Canada, Japan, and the UK. The study highlights that Europe risks lagging behind the US and China in pharmaceutical R&D investments and clinical trials. It presents two scenarios: a pro-innovation path fostering stable intellectual property and efficient regulation, and a contra-innovation path with cost containment measures that may increase long-term healthcare costs.

The report emphasizes that pharmaceutical innovation should be viewed as a long-term investment that can reduce future healthcare spending and enhance economic competitiveness. It suggests that a pro-innovation policy could lead to significant healthcare savings and the creation of additional life sciences companies in Europe. Shashank Deshpande, Chairman of the Board of Managing Directors at Boehringer Ingelheim, said “Pharmaceutical innovations should not be seen simply as a cost for healthcare systems.”

CREDIT: Boehringer Ingelheim
Original release on GlobeNewswire